Assessment of Systemic and Maxillary Bone Loss in Cancer Patients with Endo-Periodontal Lesions Using Dkk-1 Biomarker and Dental Radiological Examinations
Authors:
- Cristina AntohiCACristina Antohi
- Mihaela SalceanuMSMihaela Salceanu
- Liana AminovLALiana Aminov
- Maria-Alexandra MartuMaria-Alexandra Martu
- Cristina Gena DascaluCDCristina Gena Dascalu
- Gianina DodiGianina Dodi
- George StoicaGSGeorge Stoica
- Geanina BandolGBGeanina Bandol
- Dragos IancuDIDragos Iancu
- Bogdan DobrovatBDBogdan Dobrovat
- Danisia HabaDHDanisia Haba
Open Access
- 22 May 2022
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 12 (10) , 5235
Abstract
The aim of our study was to correlate systemic bone loss by evaluating human Dickkopf-related protein 1 (Dkk-1) biomarker compared to horizontal bone loss as well as the presence and size of periapical lesions assessed by dental X-ray (ortopantomography—OPT) and cone beam computed tomography (CBCT) in patients with cancer in the ears, nose and throat (ENT) region vs. healthy controls. The study included 63 subjects divided into a study group of 33 cancer patients with ENT cancer (larynx/oropharynx/sinuses) and a control group of 30 healthy individuals. Blood samples were collected from both groups to assess Dkk-1 level using a sandwich enzyme immunoassay. The dental radiological examination consisted of a panoramic X-ray and a CBCT in order to appraise the horizontal bone loss, the presence and size of the periapical lesions in 2D vs. 3D images. The panoramic X-ray showed that in the control group, the maximum bone loss reached 13.2 mm, with an average of 4.930 ± 3.258 mm, while in the study group, the maximum horizontal bone loss was 11.3 mm, with an average of 5.191 ± 2.109 mm. The CBCT 3D investigation, when compared to the OPT, showed increased values for horizontal bone loss, both in the control group and in the study group; in the control group, the maximum bone loss reached 14.10 mm, with an average of 5.736 ± 3.471 mm, and in the study group, the maximum value was 12.40 mm, and the average was again slightly higher (6.152 ± 2.519 mm). The mean value for Dkk-1 in cancer patients was 1.209 ± 0.110 ng/mL, significantly lower than the value observed in healthy patients (1.712 ± 0.100 ng/mL). CBCT revealed higher values for the investigated parameters when compared to panoramic X-rays. Taking into account the preliminary nature of our study, we observed a significant correlation between the level of bone loss recorded by the Dkk-1 biomarker and radiological dental examination in patients with ENT cancer when compared to the control group.Keywords
This publication has 48 references indexed in Scilit:
- Dickkopf1: A tumor suppressor or metastasis promoter?International Journal of Cancer, 2011
- Clinicopathological and prognostic significance of serum and tissueDickkopf‐1levels in human hepatocellular carcinomaLiver International, 2011
- Circulating Dickkopf-1 Is Correlated with Bone Erosion and Inflammation in Rheumatoid ArthritisThe Journal of Rheumatology, 2011
- Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosisBone, 2010
- Dose–response relationship between periodontal inflamed surface area and HbA1c in type 2 DiabeticsJournal of Clinical Periodontology, 2009
- The role of Dickkopf-1 in bone development, homeostasis, and diseaseBlood, 2009
- Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasisThe Prostate, 2008
- Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSFMolecular Cancer, 2007
- Function and biological roles of the Dickkopf family of Wnt modulatorsOncogene, 2006
- Alveolar bone loss in adults as assessed on panoramic radiographs. (II) Multilevel modelsClinical Oral Investigations, 2005